=> d his

(FILE 'HOME' ENTERED AT 10:48:03 ON 30 SEP 2004)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, AQUALINE, ANABSTR, ANTE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DISSABS, DDFB, DDFU, DGENE, ...' ENTERED AT 10:48:16 ON 30 SEP 2004 SEA CYCLOOXYGENASE OR COX

		_
4273	FILE	ADISCTI
108		ADISINSIGHT
336	FILE	
907	FILE	
46		AOUALINE
91	FILE	~
45	FILE	ANTE
487	FILE	
497		BIOBUSINESS
33		BIOCOMMERCE
264	FILE	
40750	FILE	
201		BIOTECHABS
201		BIOTECHDS
6561	FILE	
4278		CABA
10632		CANCERLIT
28655		CAPLUS
128		CEABA-VTB
60	FILE	
717	FILE	
546	FILE	
12		CROPB
123	FILE	
2300	FILE	
99	FILE	DDFB
9941	FILE	DDFU
2189	FILE	
99	FILE	DRUGB
325	FILE	DRUGMONOG2
255	FILE	IMSDRUGNEWS
12058	FILE	
157	FILE	IMSRESEARCH
742	FILE	
36343	FILE	EMBASE
16125	FILE	
1076	FILE	FEDRIP
95	FILE	FOMAD
279	FILE	FROSTI
	FILE	
530 17034		GENBANK
240	FILE	
2118		
2118 89	FILE	IFIPAT
	FILE FILE	IMSPRODUCT
3089		JICST-EPLUS
28	FILE	KOSMET
4509		LIFESCI
58	FILE	MEDICONF
39369	FILE	MEDLINE
133	FILE	NIOSHTIC
468	FILE	NTIS
8	FILE	NUTRACEUT

212

19324

FILE OCEAN

FILE PASCAL

```
FILE PHAR
  781
       FILE PHARMAML
  377
       FILE PHIC
  6
       FILE PHIN
 1124
       FILE PROMT
41169
 2333
       FILE PROUSDDR
  31
       FILE RDISCLOSURE
       FILE SCISEARCH
36182
  57
       FILE SYNTHLINE
22459
       FILE TOXCENTER
14790
       FILE USPATFULL
 1064
       FILE USPAT2
 245
        FILE VETU
 119
        FILE WATER
 3187
        FILE WPIDS
  14
       FILE WPIFV
 3187
      FILE WPINDEX
    QUE CYCLOOXYGENASE OR COX
    ______
```

FILE 'PROMT, BIOSIS, MEDLINE, EMBASE, SCISEARCH, CAPLUS, TOXCENTER, PASCAL, ESBIOBASE, DRUGU, CANCERLIT' ENTERED AT 10:50:40 ON 30 SEP 2004

524 S L1 AND OSTEOSARCOMA Ь2 L3

L1

5 S L2 AND (143.98.2)

2 DUP REM L3 (3 DUPLICATES REMOVED) L4

=> d 14 ibib ab 1-2

L4 ANSWER 1 OF 2 MEDLINE on STN DUPLICATE 1

ACCESSION NUMBER: 97239482 MEDLINE DOCUMENT NUMBER: PubMed ID: 9085144

TITLE: Characterization of autocrine inducible prostaglandin H

synthase-2 (PGHS-2) in human osteosarcoma cells.

AUTHOR: Wong E; DeLuca C; Boily C; Charleson S; Cromlish W; Denis

D; Kargman S; Kennedy B P; Ouellet M; Skorey K; O'Neill G

P; Vickers P J; Riendeau D

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Merck

Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, Quebec, Canada.

SOURCE: Inflammation research : official journal of the European

Histamine Research Society ... [et al.], (1997 Feb) 46 (2)

51-9.

Journal code: 9508160. ISSN: 1023-3830.

PUB. COUNTRY: Switzerland

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199706

ENTRY DATE: Entered STN: 19970620

Last Updated on STN: 19970620 Entered Medline: 19970612

AB The human osteosarcoma 143.98.2

cell line was found to express high levels of prostaglandin synthase-2 (PGHS-2) without detectable levels of prostaglandin synthase-1 (PGHS-1) as measured by reverse transcriptase-polymerase chain reaction (RT-PCR) and immunoblot analysis. Maximal levels of PGHS-2 induction were attained when the cells were grown beyond confluence. The osteosarcoma cells also secrete IL-1 alpha, IL-1 beta and TNF alpha in the culture medium. PGHS-2 expression was inducible by the exogenous addition of these cytokines as well as conditioned media from auto-induced cultures and inhibitable by treatment with dexamethasone. In contrast, undifferentiated U937 cells selectively express PGHS-1 as analyzed by RT-PCR and Western blotting. The effects of non-steroidal anti-inflammatory drugs (NSAIDs) on the cellular PGE2 production mediated by each isoform of human PGHS were determined using osteosarcoma and undifferentiated U937 cells. When cells were preincubated with inhibitors to allow time-dependent inhibition prior to arachidonic acid stimulation, NS-398, CGP 28238, L-745,337, SC-58125 all behaved as potent (IC50 = 1-30 nM) and selective inhibitors of PGHS-2, in contrast to indomethacin, flurbiprofen or diclofenac which are potent inhibitors of enzymes. DuP-697 and sulindac sulfide were also potent inhibitors of PGHS-2 but both compounds inhibited cellular PGHS-1 activity at higher doses (IC50 = 0.2-0.4 microM). Time-dependent inhibition of PGE2 production in osteosarcoma cells was observed for indomethacin, diclofenac and etodolac. The synthesis of PGE2 by U937 cells was strongly dependent on exogenous arachidonic acid (100-fold stimulation) whereas confluent osteosarcoma cells also produced PGE2 without exogenous stimulus (7-fold stimulation by arachidonic acid). Osteosarcoma cells grown beyond confluence released more PGE2 from endogenous substrate than arachidonic acid stimulated undifferentiated U937 cells. These results indicate that osteosarcoma cells selectively express PGHS-2 with an autocrine regulation and effective utilization of endogenous arachidonic acid for PGE2 synthesis.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 1995:339482 CAPLUS

DOCUMENT NUMBER: 122:105655

TITLE: Preparation of 2-substituted-3,4-di(aryl)thiophene

cyclooxygenase inhibitors

INVENTOR(S):

Gauthier, Jacques Yves; Leblanc, Yves; Prasit,

Petpiboon

PATENT ASSIGNEE(S):

Merck Frosst Canada Inc., Can.

SOURCE:

PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 9426731	A1 19941124	WO 1994-CA264	19940511
W: AU, BB, BG,	BR, BY, CA, CN,	CZ, FI, HU, JP, KR,	KZ, LK, LV, MG,
MN, MW, NO,	NZ, PL, RO, RU,	SD, SI, SK, TT, UA,	US, UZ
RW: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IE, IT, LU,	MC, NL, PT, SE,
BF, BJ, CF,	CG, CI, CM, GA,	GN, ML, MR, NE, SN,	TD, TG
CA 2161789	AA 19941124	CA 1994-2161789	19940511
AU 9467184	A1 19941212	AU 1994-67184	19940511
PRIORITY APPLN. INFO.:		US 1993-61354	A 19930513
		WO 1994-CA264	W 19940511

OTHER SOURCE(S): MARPAT 122:105655

AB The title compds. [I; R1 = H, halogen, CN, NO2, CF3, C1-6 alkyl; R2 = C3-6 alkyl, (un) substituted Ph, (un) substituted heteroaryl; R3 = SO2CH3, S(O) (NH) CH3, SONH2, SO2NH2; R4 = H, halogen, CO2H, CF3], useful as cyclooxygenase inhibitors, are prepared and I-containing formulations claimed. Thus, 3-(4-fluorophenyl)-4-(4-sulfamoylphenyl) thiophene was prepared and demonstrated 95% inhibition of PGE2 formation by osteosarcoma (143.98.2) cells at 100 nM.







PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book Search PubMed Clear for Go ✓ Limits Preview/Index History Clipboard Details Show: 20 Display Abstract Sort Send to Text About Entrez

ADOUT LINE

**Text Version** 

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Maris

□ 1: Inflamm Res. 1997 Feb;46(2):51-9.

Related Articles, L

Springer Link

Characterization of autocrine inducible prostaglandin H synthase-2 (PGH 2) in human osteosarcoma cells.

Wong E, DeLuca C, Boily C, Charleson S, Cromlish W, Denis D, Kargman S, Kennedy BP, Ouellet M, Skorey K, O'Neill GP, Vickers PJ, Riendeau D.

Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeut Research, Pointe-Claire-Dorval, Quebec, Canada.


The human osteosarcoma 143.98.2 cell line was found to express high levels of prostaglandin synthase-2 (PGHS-2) without detectable levels of prostaglandin synthase-(PGHS-1) as measured by reverse transcriptase-polymerase chain reaction (RT-PCR) an immunoblot analysis. Maximal levels of PGHS-2 induction were attained when the cells were grown beyond confluence. The osteosarcoma cells also secrete IL-1 alpha, IL-1 bet and TNF alpha in the culture medium. PGHS-2 expression was inducible by the exogeno addition of these cytokines as well as conditioned media from auto-induced cultures and inhibitable by treatment with dexamethasone. In contrast, undifferentiated U937 cells selectively express PGHS-1 as analyzed by RT-PCR and Western blotting. The effects o non-steroidal anti-inflammatory drugs (NSAIDs) on the cellular PGE2 production media by each isoform of human PGHS were determined using osteosarcoma and undifferentia U937 cells. When cells were preincubated with inhibitors to allow time-dependent inhibition prior to arachidonic acid stimulation, NS-398, CGP 28238, L-745,337, SC-58125 all behaved as potent (IC50 = 1-30 nM) and selective inhibitors of PGHS-2, in contrast to indomethacin, flurbiprofen or diclofenac which are potent inhibitors of enzymes. DuP-697 and sulindac sulfide were also potent inhibitors of PGHS-2 but both compounds inhibited cellular PGHS-1 activity at higher doses (IC50 = 0.2-0.4 microM). Time-dependent inhibition of PGE2 production in osteosarcoma cells was observed for indomethacin, diclofenac and etodolac. The synthesis of PGE2 by U937 cells was strong dependent on exogenous arachidonic acid (100-fold stimulation) whereas confluent osteosarcoma cells also produced PGE2 without exogenous stimulus (7-fold stimulation arachidonic acid). Osteosarcoma cells grown beyond confluence released more PGE2 fro endogenous substrate than arachidonic acid stimulated undifferentiated U937 cells. Thes results indicate that osteosarcoma cells selectively express PGHS-2 with an autocrine regulation and effective utilization of endogenous arachidonic acid for PGE2 synthesis.

PMID: 9085144 [PubMed - indexed for MEDLINE]





• Click on query # to add to strategy



			•						
Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Book
Search P	ubMed	☑ for ‡	#1 AND #2			Pr	eview C	Go Clear	
		<b>☑</b> Limits	Preview/Index	Histo	ry	Clipboard	De	etails	-
About Entrez	<u>.</u>	<ul> <li>Search History will be lost after eight hours of inactivity.</li> <li>To combine searches use # before search number, e.g., #2 AND #6.</li> <li>Search numbers may not be continuous; all searches are represented.</li> </ul>							
T. (1)/		<ul> <li>Search number</li> </ul>	ers may not be o	continuous; a	II searche	s are represer	itea.		

**Text Version** 

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher Clinical Queries** LinkOut Cubby

Related Resources **Order Documents NLM Catalog NLM Gateway TOXNET** Consumer Health **Clinical Alerts** ClinicalTrials.gov PubMed Central

Sear	ch Most Recent Queries	Time	Res
Ĩ	#3 Search #1 AND #2 Field: Title, Limits: Publication Date from 1970 to 1992	10:55:53	_
<u> 1</u>	44 Search #1 AND #2 Field: Text Word, Limits: Publication Date from 1970 to 1992	10:55:41	_
<u>1</u>	Search osteosarcoma Field: Title, Limits: Publication Date from 1970 to 1992	10:55:02	20
·	El Search cyclooxygenase OR COX Field: Title, Limits: Publication  Date from 1970 to 1992	10:54:39	8

Clear History

Write to the Help Desk NCBI | NLM | NIH
Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer

Sep 21 2004 15:







Go

Entrez

PubMed

Nucleotide

otide

Protein

Genome

Structure

OMIM

PMC

Journals

Book

Search PubMed

☑ 1 ☑ Limits

for #1 AND #2

Preview/Index

History

Clipboard

Clear

Details

No items found.

**About Entrez** 

**Text Version** 

Field: Title, Limits: Publication Date from 1970 to 1992

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Catalog NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Sep 21 2004 15: